SEC Form 6-K filed by PureTech Health plc

8/28/24 7:29:31 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PRTC alert in real time by email

ptv-20240630

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

For the month of June 2024

Commission File Number 001-39670

PURETECH HEALTH PLC

(Translation of registrant’s name into English)

6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On August 28, 2024, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) issued a press release containing its half-year report along with the Interim Management Report and Financial Review for the Six Months Ended June 30, 2024 and 2023, and the associated Unaudited Condensed Consolidated Financial Statements as of and for the Six Months Ended June 30, 2024 and 2023 and as of December 31, 2023, which are furnished herewith as Exhibit 99.1, Exhibit 99.2 and 99.3, respectively, and are incorporated by reference herein.

Exhibits


99.1						Press Release of PureTech Health plc, dated August 28, 2024, titled "PureTech Health plc – Half-Year Report"
99.2						Interim Management Report and Financial Review for the Six Months Ended June 30, 2024 and 2023
99.3						Unaudited Condensed Consolidated Financial Statements as of and for the Six Months Ended June 30, 2024 and 2023 and as of December 31, 2023

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	PURETECH HEALTH PLC

Date: August 28, 2024	By:	/s/ Bharatt Chowrira
	Name:	Bharatt Chowrira
	Title:	Chief Executive Officer

Get the next $PRTC alert in real time by email

Date

Price Target

Rating

Analyst

9/9/2024

$58.00 → $45.00

Outperform

Leerink Partners

1/7/2022

$76.00 → $70.00

Outperform

SVB Leerink

8/25/2021

$74.00 → $76.00

Outperform

SVB Leerink

SEC Form 6-K filed by PureTech Health plc

Chat with this insight

Recent Analyst Ratings for
$PRTC

$PRTC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Leerink Partners resumed coverage on PureTech Health plc with a new price target

SVB Leerink reiterated coverage on PureTech Health with a new price target

SVB Leerink reiterated coverage on PureTech Health with a new price target

$PRTC
SEC Filings